Compare · LABT vs NVO
LABT vs NVO
Side-by-side comparison of Lakewood-Amedex Biotherapeutics Inc. (LABT) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LABT and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $178.51B, about 193157.6x LABT ($924,178).
- Over the past year, LABT is down 99.5% and NVO is down 11.7% - NVO leads by 87.7 points.
- NVO has been more active in the news (7 items in the past 4 weeks vs 3 for LABT).
- NVO has more recent analyst coverage (25 ratings vs 1 for LABT).
- Company
- Lakewood-Amedex Biotherapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $924,178
- $178.51B
- 1M return
- -56.12%
- +5.61%
- 1Y return
- -99.47%
- -11.73%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 7
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LABT
- Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock Redemption
- H.C. Wainwright initiated coverage on Lakewood-Amedex Biotherapeutics with a new price target
- Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026
- Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds
- Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences
- Lakewood-Amedex Biotherapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers
- SEC Form EFFECT filed by Lakewood-Amedex Biotherapeutics Inc.
- Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
- Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S